Bird Rock Bio is a clinical stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators. Backed by leading biotechnology venture investors, our strategy leverages biologic targets with substantial human proof of mechanism for the development of novel, best-in-class therapeutic antibodies with significant clinical and commercial differentiation.
Home
News
- May 28, 2020
Bird Rock Bio Files IND Application for Phase 2 Study of Nimacimab for Treatment of Renal Diseases - October 17, 2019
Bird Rock Bio Announces Successful Completion of Phase 1B Safety Study and Readiness for Phase 2B Study of Nimacimab in Patients with Diabetic Kidney Disease - September 13, 2018
Bird Rock Bio Completes Clinical Trial of Nimacimab in Patients with Fatty Liver Disease